Aridis Pharmaceuticals Inc ARDS

NAS: ARDS | ISIN: US0403341045   28/04/2025
0,000 USD (0,00%)
(0,00%)   28/04/2025

4 oktober 2022 · Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study · Persbericht

27 september 2022 · Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock · Persbericht

26 september 2022 · Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock · Persbericht

16 augustus 2022 · Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Update · Persbericht

10 augustus 2022 · Aridis' Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective in Non-Human Primates · Persbericht

3 juni 2022 · Aridis Pharmaceuticals CEO to Participate in a Fireside Chat Presented by Maxim Group LLC and Hosted by M-Vest on June 7 · Persbericht

16 mei 2022 · Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update · Persbericht

1 april 2022 · Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update · Persbericht

17 februari 2022 · Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals · Persbericht

27 januari 2022 · Aridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission · Persbericht

10 november 2021 · Aridis Pharmaceuticals Announces Third Quarter 2021 Results · Persbericht

12 augustus 2021 · Aridis Pharmaceuticals Announces Second Quarter 2021 Results · Persbericht

2 augustus 2021 · Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market · Persbericht

26 juli 2021 · Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC) · Persbericht

19 juli 2021 · Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca · Persbericht

12 juli 2021 · Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant · Persbericht

11 mei 2021 · Aridis Pharmaceuticals Announces First Quarter 2021 Results · Persbericht

30 maart 2021 · Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update · Persbericht

26 maart 2021 · Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report® · Persbericht

8 maart 2021 · Aridis Enters into APEX™ Licensing and Product Discovery Agreement for Zoonotic Viruses with Kermode · Persbericht

Mijn selecties